Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an agreement with Ypsomed AG, the manufacturer and supplier of the pen injector device to be used in connection with its...

Q1 Business and Financial Highlights: Net Sales were $75.1 Million Gross Margin 17%, Adjusted Gross Margin 18% Net Sales, Gross Margin and Adjusted Gross Margin Increased from Preceding Quarter...

Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2023 first quarter on Wednesday, November 2, 2022, after the market closes. Lannett...

Lannett Company, Inc. (NYSE: LCI) today announced that it has received approval from the US Food and Drug Administration (FDA) to manufacture Numbrino®, the company's branded topical anesthetic...

-Companies Entered Into a Separate Private Label Agreement for Certain Other Lannett Generic Products- PHILADELPHIA, Oct. 19, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced...

No Reported Serious Adverse Events; Topline Results Expected Later This Year TREVOSE, Pa., Aug. 31, 2022 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that subject dosing has...

Q4 Business and Financial Highlights: Net Sales were $74.2 Million Adjusted Gross Margin Better than Expected, Improved vs Q3 Cash Was $88 Million at June 30 Completed Major Elements of November...

Trevose, PA – August 19, 2022 – Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2022 fourth quarter and full year on Wednesday, August...

Approximately Half of the Planned Number of Subjects Have Received the First Dose, With No Reported Serious Adverse Events Study Progressing On Schedule Topline Results Expected Later This Year...

-- Current Drug Market Shortage Exists for Fludarabine Phosphate, An Injectable Chemotherapeutic Medication; Marketing Anticipated to Commence Later This Calendar Year -- PHILADELPHIA, May 12,...

Q3 Business and Financial Highlights: Net Sales were $78.4 Million Cash in Excess of $106 Million at March 31 Completed Sale of Liquid Manufacturing Plant for $10.5 Million; Major Elements of...

Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2022 third quarter on Wednesday, May 4, 2022, after the market closes. Lannett management...

--First Patient Dosed, Topline Study Results Expected Later This Year; Potential BLA Filing in Early 2023 and Launch in the First Half of 2024-- TREVOSE, Pa., March 29, 2022 /PRNewswire/ --...

Lannett Company, Inc. (NYSE: LCI) today announced that it has received written notice from the New York Stock Exchange (NYSE) dated March 14, 2022, notifying the company that it is not in...

Lannett Company, Inc. (NYSE: LCI) today announced that the company will participate in a fireside chat at the 34th Annual ROTH Conference on March 14, 2022 at 12:30 p.m. PT at The Ritz Carlton, in...

Lannett Company, Inc. (NYSE: LCI) today announced that it has received written notice from the New York Stock Exchange (NYSE) dated March 2, 2022, notifying the company that it is not in...

Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into material definitive agreements to sell its liquid drug manufacturing facility in Carmel, NY, as well as equipment located...

Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2022 second quarter ended December 31, 2021. "For the quarter, ongoing and increasing competitive pricing pressure...

Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2022 second quarter on Thursday, February 3, 2022, after the market closes. Lannett...

Lannett Company, Inc. (NYSE: LCI) today announced that the U.S. Food and Drug Administration (FDA) has notified the company that they have completed the safety review of the Investigational New...